Accessibility Menu
Interpace Biosciences logo

Interpace Biosciences(OTC) IDXG

Market Cap$42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1998)-100%
5 Year-83%
1 Year+76%
1 Month-6%
$1.52
+5.35%
+0.08Today
Interpace Biosciences last closing stock price
MetricPriceDate
Last closeUSD 1.522026-07-31
Interpace Biosciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.9%USD 1.462026-07-24
1 month-5.78%USD 1.612026-07-01
3 month-28.44%USD 2.122026-05-01
Year to date+23.31%USD 1.232025-12-31
1 year+76.4%USD 0.862025-07-31
3 year-21.4%USD 1.932023-08-01
5 year-82.66%USD 8.752021-07-30
Since inception-99.93%USD 2,162.501998-05-20

Interpace Biosciences Financials at a Glance

Market Cap

$42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$36.25M

Net Income (TTM)

$23.65M

EPS (TTM)

$0.73

P/E Ratio

2.07

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$1.52

Volume

100

Open

$1.52

Previous Close

$1.52

Daily Range

$1.52 - $1.52

52-Week Range

$0.77 - $2.40

Estimated Earnings Date

May 7, 2026

IDXG News

Foolcom-Featured.png

Interpace Biosciences Earnings Drop

Motley Fool Markets TeamAug 8, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Interpace Biosciences

Interpace helps doctors assess cancer risk using lab tests and data analysis. Its services support hospitals and clinics in making treatment decisions. These tools aim to clarify uncertain biopsy results for patients and physicians.

Lab Test Lineup: What’s in the Interpace Toolbox?

  • ThyGeNEXT: Detects genetic changes in thyroid nodules to help identify cancer risk; used by endocrinologists and surgeons.
  • ThyraMIR: Analyzes microRNA patterns in thyroid nodules to assess malignancy risk; often paired with ThyGeNEXT.
  • RespriDx: Differentiates between new and recurring lung cancers using DNA analysis; supports oncologists in treatment planning.
  • PanDNA: Offers a focused genetic test for pancreatic lesions; used by gastroenterologists for risk assessment.
  • Pharmacogenomics and Biorepository Services: Provides drug response testing and sample storage for pharmaceutical and biotech companies.

Growth Spurts and Strategic Moves

  • Discontinued PancraGEN test in May 2025 after loss of Medicare coverage.
  • Restructured operations and reduced workforce in Q2 2025 to cut costs.
  • Exploring new funding sources and business partnerships in the context of removal from Nasdaq (in 2021) and impending removal from OTCQX in August 2025.
  • Provides pharmacogenomics and custom lab services for biotech clients.

What Makes Interpace Stand Out?

Interpace focuses on personalized cancer diagnostics, combining genetic testing with data analysis for clearer results. Its integrated approach helps doctors make informed decisions for complex cancer cases.

Five Things You Need to Know

  • Q2 2025 revenue was $9.2 million, down 23.3% from Q2 2024.
  • Gross margin fell to 57.1% in Q2 2025 from 64.8% a year earlier.
  • All revenue comes from U.S. clinical services; no international sales reported.
  • Cash and cash equivalents were $0.5 million as of June 30, 2025.
  • Two private equity investors control 84% of shares (as-converted basis).

Bottom Line

Interpace has shifted focus after losing a key product and faces funding challenges. Its core business remains specialized cancer diagnostics for U.S. healthcare providers.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

102

CEO

Thomas W. Burnell, PhD

Website

www.interpacediagnostics.com

Headquarters

Parsippany, NJ 07054, US

IDXG Financials

Key Financial Metrics (TTM)

Gross Margin

62.53%

Operating Margin

9.32%

Net Income Margin

65.25%

Return on Equity

215.31%

Return on Capital

17.34%

Return on Assets

70.79%

Earnings Yield

48.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

27.70M

Volume

100

Avg. Volume

5.45K

Financials (TTM)

Gross Profit

$22.66M

Operating Income

$3.38M

EBITDA

$4.07M

Operating Cash Flow

$4.88M

Capital Expenditure

-$497.00K

Free Cash Flow

$4.38M

Cash & ST Invst.

$2.65M

Total Debt

$1.08M

Interpace Biosciences Performance Analysis

Interpace Biosciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 31,838,000-3.9%
20232023-12-31USD 40,036,00025.7%
20242024-12-31USD 46,926,00017.2%
20252025-12-31USD 38,728,000-17.5%
Interpace Biosciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-19.8%
Q32025-09-30-5.2%
Q42025-12-315.4%
Q12026-03-31-2.1%
Interpace Biosciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -5.1843.4%
20232023-12-31USD 0.45N/A
20242024-12-31USD 0.40-11.5%
20252025-12-31USD 0.89123.8%
Interpace Biosciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-333.3%
Q32025-09-30123.5%
Q42025-12-312392.4%
Q12026-03-31-96.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$9.03M

-21.6%

Gross Profit

$5.90M

-19.9%

Gross Margin

65.37%

N/A

Market Cap

$42.02MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$411.98K

N/A

Employees

102

N/A

Net Income

$721.00K

-56.2%

EBITDA

$1.35M

-33.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$2.65M

+121.3%

Total Debt

$1.08M

-74.5%

Accounts Receivable

$5.93M

-32.4%

Inventory

$961.00K

-20.5%

Long Term Debt

$635.00K

-41.2%

Short Term Debt

$445.00K

-85.9%

Return on Assets

70.79%

N/A

Return on Invested Capital

11.47%

N/A

Free Cash Flow

$142.00K

-88.5%

Operating Cash Flow

$283.00K

-77.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RVVTFRevive Therapeutics Ltd.
$0.02+11.11%
CPIVFCaptiva Verde Wellness Corp.
$0.02-44.41%
RSCFReflect Scientific, Inc.
$0.04+0.00%
LIFDLFTD Partners Inc.
$0.20+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About IDXG

What is the current price of Interpace Biosciences?

Interpace Biosciences is trading at $1.52 per share.

What is the 52-week range for Interpace Biosciences?

Over the past 52 weeks, Interpace Biosciences has traded between $0.77 and $2.40.

How much debt does Interpace Biosciences have?

As of the most recent reporting period, Interpace Biosciences reported total debt of $1.08M.

How much cash does Interpace Biosciences have on hand?

Interpace Biosciences reported $2.65M in cash and cash equivalents in its most recent financial results.

What is Interpace Biosciences’s dividend yield?

Interpace Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services